Literature DB >> 11257032

Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata.

D Sanglard1, F Ischer, J Bille.   

Abstract

Candida glabrata has been often isolated from AIDS patients with oropharyngeal candidiasis treated with azole antifungal agents, especially fluconazole. We recently showed that the ATP-binding-cassette (ABC) transporter gene CgCDR1 was upregulated in C. glabrata clinical isolates resistant to azole antifungal agents (D. Sanglard, F. Ischer, D. Calabrese, P. A. Majcherczyk, and J. Bille, Antimicrob. Agents Chemother. 43:2753-2765, 1999). Deletion of CgCDR1 in C. glabrata rendered the null mutant hypersusceptible to azole derivatives and showed the importance of this gene in mediating azole resistance. We observed that wild-type C. glabrata exposed to fluconazole in a medium containing the drug at 50 microg/ml developed resistance to this agent and other azoles at a surprisingly high frequency (2 x 10(-4) to 4 x 10(-4)). We show here that this high-frequency azole resistance (HFAR) acquired in vitro was due, at least in part, to the upregulation of CgCDR1. The CgCDR1 deletion mutant DSY1041 could still develop HFAR but in a medium containing fluconazole at 5 microg/ml. In the HFAR strain derived from DSY1041, a distinct ABC transporter gene similar to CgCDR1, called CgCDR2, was upregulated. This gene was slightly expressed in clinical isolates but was upregulated in strains with the HFAR phenotype. Deletion of both CgCDR1 and CgCDR2 suppressed the development of HFAR in a medium containing fluconazole at 5 microg/ml, showing that both genes are important mediators of resistance to azole derivatives in C. glabrata. We also show here that the HFAR phenomenon was linked to the loss of mitochondria in C. glabrata. Mitochondrial loss could be obtained by treatment with ethidium bromide and resulted in acquisition of resistance to azole derivatives without previous exposure to these agents. Azole resistance obtained in vitro by HFAR or by agents stimulating mitochondrial loss was at least linked to the upregulation of both CgCDR1 and CgCDR2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11257032      PMCID: PMC90441          DOI: 10.1128/AAC.45.4.1174-1183.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Multiple resistance mechanisms to azole antifungals in yeast clinical isolates.

Authors:  D Sanglard; F Ischer; D Calabrese; M Micheli; J Bille
Journal:  Drug Resist Updat       Date:  1998       Impact factor: 18.500

2.  Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors:  Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal:  Microbiology (Reading)       Date:  1997-02       Impact factor: 2.777

Review 3.  Molecular mechanisms of drug resistance in fungi.

Authors:  H Vanden Bossche; P Marichal; F C Odds
Journal:  Trends Microbiol       Date:  1994-10       Impact factor: 17.079

4.  In-vitro resistance to imidazole antifungals in Candida albicans.

Authors:  E M Johnson; M D Richardson; D W Warnock
Journal:  J Antimicrob Chemother       Date:  1984-06       Impact factor: 5.790

5.  In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata.

Authors:  Alain Defontaine; Jean-Philippe Bouchara; Philippe Declerk; Claire Planchenault; Dominique Chabasse; Jean-Noel Hallet
Journal:  J Med Microbiol       Date:  1999-07       Impact factor: 2.472

6.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

7.  In-vivo selection of an azole-resistant petite mutant of Candida glabrata.

Authors:  Jean-Philippe Bouchara; Rachid Zouhair; Sandrine LE Boudouil; Gilles Renier; Robert Filmon; Dominique Chabasse; Jean-Noel Hallet; Alain Defontaine
Journal:  J Med Microbiol       Date:  2000-11       Impact factor: 2.472

8.  Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans.

Authors:  K A Marr; C N Lyons; K Ha; T R Rustad; T C White
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

10.  Molecular cloning and expression of the Saccharomyces cerevisiae STS1 gene product. A yeast ABC transporter conferring mycotoxin resistance.

Authors:  P H Bissinger; K Kuchler
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

View more
  100 in total

Review 1.  Mechanisms of fungal resistance: an overview.

Authors:  Maher M Balkis; Steven D Leidich; Pranab K Mukherjee; Mahmoud A Ghannoum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Mitochondrial sorting and assembly machinery subunit Sam37 in Candida albicans: insight into the roles of mitochondria in fitness, cell wall integrity, and virulence.

Authors:  Yue Qu; Branka Jelicic; Filomena Pettolino; Andrew Perry; Tricia L Lo; Victoria L Hewitt; Farkad Bantun; Traude H Beilharz; Anton Y Peleg; Trevor Lithgow; Julianne T Djordjevic; Ana Traven
Journal:  Eukaryot Cell       Date:  2012-01-27

3.  Secreted aspartate proteinases, a virulence factor of Candida spp.: occurrence among clinical isolates.

Authors:  P Hamal; J Dostál; V Raclavský; M Krylová; I Pichová; O Hrusková-Heidlngsfeldová
Journal:  Folia Microbiol (Praha)       Date:  2004       Impact factor: 2.099

4.  A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole.

Authors:  Shaoji Cheng; Cornelius J Clancy; Katherine T Nguyen; William Clapp; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

Review 5.  Multidrug resistance in fungi.

Authors:  Kailash Gulshan; W Scott Moye-Rowley
Journal:  Eukaryot Cell       Date:  2007-09-14

6.  Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata.

Authors:  Sarah G Whaley; Qing Zhang; Kelly E Caudle; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

7.  Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).

Authors:  Amar Safdar; Vishnu Chaturvedi; Brian S Koll; Davise H Larone; David S Perlin; Donald Armstrong
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

9.  Azole resistance in Candida glabrata: coordinate upregulation of multidrug transporters and evidence for a Pdr1-like transcription factor.

Authors:  John-Paul Vermitsky; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation.

Authors:  Spencer W Redding; William R Kirkpatrick; Stephen Saville; Brent J Coco; William White; Annette Fothergill; Michael Rinaldi; Tony Eng; Thomas F Patterson; Jose Lopez-Ribot
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.